<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02358668</url>
  </required_header>
  <id_info>
    <org_study_id>SG01</org_study_id>
    <nct_id>NCT02358668</nct_id>
  </id_info>
  <brief_title>BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in Subjects With Pre-Diabetes</brief_title>
  <official_title>A Study to Evaluate the Effect of BTI320 (SUGARDOWN®) on Post-Prandial Hyperglycaemia in High Risk Chinese Subjects With Pre-Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Sugardown Company Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Chinese University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a single-centre, 16-week, randomized, double-blind, placebo-controlled, 3-treatment
      arm pilot study to evaluate the efficacy and safety of BTI320 in the treatment of high risk
      subjects with pre-diabetes.

      This is a pilot study aiming to test whether taking a medicine named BTI320 that slows down
      carbohydrate absorption in the gut, will lower blood sugar. The study aims to recruit 60
      individuals in Hong Kong. To take part in the study, subjects must have pre-diabetes, that
      is, they have blood sugar levels that are above normal but not reaching diabetes range. The
      medicine BTI320 is currently licensed as a health supplement in Hong Kong and is known
      alternatively as SUGARDOWN®. The investigators are comparing the effectiveness of BTI320
      against a dummy tablet. Both tablets look and taste identical and during the study, subjects
      will not know which of these tablets they are taking. There is a 4 in 5 chance of receiving
      active medication and 1 in 5 chance of receiving placebo. Subjects will be followed up
      closely every 2 to 4 weeks for a period of time up to 22 weeks.

      The study visits will take between 30 minutes to 3 hours, depending on additional checks that
      are required on a particular visit including oral glucose tolerance test and meal tolerance
      test. At visits involving meal tolerance test, subjects will be required to stay for
      approximately 3 hours. In addition, at Visit 2, Visit 4 and 3 days before Visit 7, a
      continuous glucose monitoring system device will be installed.

      Throughout the study period, subjects will return to the study center for check-ups including
      careful enquiry about whether they have developed any side-effects from taking the
      medication, physical examination, as well as blood tests.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a recent national survey, 11% of adults in China have diabetes and 50% have pre-diabetes
      defined by fasting plasma glucose (FPG) 5.6-6.9 mmol/l and/or 2-hour post glucose (PG)
      7.8-11.0 mmol/L using 75 gram oral glucose tolerance test (75g OGTT) and/or glycated
      haemoglobin (HbA1c) 5.7-6.4%. Depending on the presence of other risk factors, the annual
      conversion rate of pre-diabetes averages 3-10% with pre-diabetes associated with 1.5-2.0 fold
      increased risk for cardiovascular disease. Once diabetes is established, life expectancy is
      reduced by 6 years if not diagnosed, treated or controlled, especially in young-to-middle
      aged subjects who will face long disease duration of diabetes.

      In the Hong Kong Diabetes Registry, depending on control of glucose and other risk factors,
      3-10% of Chinese subjects with diabetes may die or develop a major event every year including
      heart disease, stroke, kidney failure and /or all-site cancer.

      Besides glycaemic control as defined by HbA1c, post prandial hyperglycaemia and glycaemic
      variability have also been shown to predict cardiovascular and renal events in both
      pre-diabetic and diabetic patient. Genetic variants discovered in large-scale epidemiological
      studies including those from China and Hong Kong have been found to be associated with beta
      cell dysfunction which can be further exacerbated by glucotoxicity and lipotoxicity, often
      due to co-existing obesity giving rise to early onset diabetes. Several studies including
      those from Asian populations indicated that subjects with pre-diabetes exhibit reduced early
      phase insulin secretion resulting in postprandial hyperglycaemia which can impose metabolic
      stress on the beta cells leading to eventual beta cell failure.

      BTI320, also known as SUGARDOWN®, is derived from galactomanan which acts by blocking the key
      carbohydrate hydrolyzing enzymes including amylase, maltose, lactose and sucrose in the
      gastrointestinal tract. It also acts to bind to ingested polysaccharides and slow their
      absorption with each meal thereby reducing post prandial glucose excursion. The mechanism of
      action for BTI320 is similar to Acarbose®, an alpha glucosidase inhibitor, which has been
      shown to improve glycaemic control and has been approved for prevention of diabetes in China.

      24-hour continuous glucose monitoring system (CGMS) measures mean blood glucose (MBG), mean
      area under the curve for blood glucose above 10mmol/l (180mg/dl) (AUC-180), mean postprandial
      maximum glucose (MPMG), mean amplitude of glucose excursion (MAGE) over 72 hours. These
      parameters correlate well with plasma fructosamine (FA) alternatively known as glycated
      albumin, which reflects short-term glycaemic control during the preceding 2 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 30, 2015</start_date>
  <completion_date type="Actual">February 19, 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</measure>
    <time_frame>From baseline to Week 4</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in 3-hour post-prandial glucose incremental area under curve on continuous glucose monitoring system from baseline to Week 16.
Note that this is not a pharmacokinetic study and this is not pharmacokinetic data as we are not measuring drug levels. Here we are examining glucose levels after meals as one of the anticipated glycemic outcomes of using glucose-lowering therapy (BTI320 in this case). With data-analysis based on continuous glucose monitoring, it is conventional to present post-prandial (i.e. post-meal) glucose incremental area under curve at up to 3 hours. It is not meaningful to look at post-meal glucose changes at more than 3 hours after meal for the obvious reason that subject might have taken another meal by then.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose BTI320 and High Dose BTI320 Compared With Placebo in Mean Post-meal Maximum Glucose on Continuous Glucose Monitoring System</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Amplitude of Glucose Excursion on Continuous Glucose Monitoring System</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Blood Glucose on Continuous Glucose Monitoring System</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve for Glucose Levels &gt;180mg/dL on Continuous Glucose Monitoring System</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Area under curve for glucose levels &gt;180 mg/dL over 72 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Glucose on Continuous Glucose Monitoring System</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation on Continuous Glucose Monitoring System</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in HbA1c in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of Glucose During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in area under curve of glucose from 0 minute to 120 minutes from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of Insulin During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in area under curve of insulin from 0 minute to 120 minutes from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of C-peptide During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in area under curve of C-peptide from 0 minute to 120 minutes from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Glucagon-like Peptide 1 During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in area under curve of glucagon-like peptide-1 from 0 minute to 120 minutes from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Subjects With Impaired Fasting Glucose or Impaired Glucose Tolerance in Low Dose BTI320, High Dose BTI320 and Placebo Group</measure>
    <time_frame>From baseline to 30 days post-treatment</time_frame>
    <description>Proportion of subjects with impaired fasting glucose, impaired glucose tolerance, both impaired fasting glucose and impaired glucose tolerance, HbA1c 5.7-6.4%, or type 2 diabetes at 30 days post-treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Pressures in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in systolic blood pressures from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Waist Circumference in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Body Weight in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Lipids in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in total cholesterol from baseline to Week 16.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in High-sensitivity C-reactive Protein in Subjects Treated With High Dose and Low Dose BTI320 Compared Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Urate in Subjects Treated With High Dose and Lose Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Quality of Life Measures in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in WHOQOL-BREF physical health domain score from baseline to Week 16. This is a sub-scale of the WHOQOL-BREF. Possible scores range from minimal of 4 to maximum of 20. Higher score indicate better physical health domain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Measures of Food Satiety in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes to question of &quot;how full do you feel&quot; in the Appetite Questionnaire adopted from Hill and Blundell from baseline and Week 16. Scale score ranges from minimum of 0 to maximum of 10. 10 being the most full and 0 being the least full.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Measures of Nutritional Intake in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in daily calories intake from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Measures of Exercise in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
    <description>Changes in the number of days per week that the subject spent walking for at least 10 minutes from baseline to Week 16</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 1 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 2 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 3 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 1 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 2 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 3 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Blood Glucose During 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Post-prandial Maximum Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Post-prandial Maximum Glucose During 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 1 Hour Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 2 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 3 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 1 Hour Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 2 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 3 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Serum Creatinine in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Measures of Liver Function in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 4, Week 8, Week 12, and Week 16</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Changes in Complete Blood Count in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</measure>
    <time_frame>From baseline to Week 4, Week 8, Week 12, and Week 16</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Pre-Diabetes</condition>
  <arm_group>
    <arm_group_label>BTI320 4 grams</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three times daily, oral for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTI320 8 grams</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>three times daily, oral for 16 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BTI320 matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 tablets three times daily, oral for 16 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTI320</intervention_name>
    <description>BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
    <arm_group_label>BTI320 4 grams</arm_group_label>
    <arm_group_label>BTI320 8 grams</arm_group_label>
    <other_name>SUGARDOWN®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTI320 matching placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>BTI320 matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Adult subjects ≥ 18-70 years inclusive

          2. Chinese ethnicity

          3. High risk subject with pre-diabetes as defined by meeting at least 2 of the following
             criteria from (a), (b) and (c):

               1. FPG ≥ 5.6-6.9 mmol/l and/or 2-hour PG ≥ 7.8-11.0 mmol/l during 75 gram OGTT

               2. HbA1c ≥ 5.7-6.4%

               3. At least one of the following risk factors:-

                    -  History of gestational diabetes

                    -  Family history of diabetes in first degree relative

                    -  2 components or more of the metabolic syndrome (triglyceride ≥ 1.7 mmol/L,
                       blood pressure (BP) ≥ 130/80 mmHg, high density-lipoprotein (HDL)
                       cholesterol &lt;1.3 mmol/L in women or &lt;1.1 in men and waist circumference ≥ 80
                       cm in women or ≥ 90 cm in men). Patients on anti-hypertensive agent for
                       treatment of hypertension or lipid lowering drug for the treatment of
                       hyperlipidaemia will respectively be considered to have one component of the
                       metabolic syndrome.

          4. Subject is capable of giving informed consent prior to the initiation of any study
             related procedures

          5. A female subject of childbearing potential who is sexually active with a
             non-sterilized male partner agrees to use routinely adequate and effective
             contraception to avoid pregnancy during the study period and up to 30 days after the
             final visit.

          6. The subject is able and willing to consistently record food diary to facilitate CGMS
             evaluation.

        Exclusion Criteria:

          1. Subject has received anti-diabetic agents within 6 weeks prior to screening visit.

          2. On dietary supplement known to affect glucose or galactose metabolism.

          3. History of acute cardiovascular disease including myocardial infarction, acute
             coronary syndrome or stroke which required hospitalization in the last 12 months.

          4. Significant renal impairment with estimated glomerular filtration rate (eGFR) &lt;
             60ml/min/1.73m2

          5. Known lactose or galactose intolerance.

          6. History of eating disorder.

          7. Pregnant or lactating female subjects.

          8. Subjects with gastrointestinal disease that may interfere with absorption of the
             investigational product.

          9. Subject has received any investigational product within 30 days of randomization
             visit.

         10. Reduced life expectancy or any condition considered by the investigator as unsuitable
             for enrolment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea OY Luk, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chinese University of Hong Kong</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Chinese University of Hong Kong</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Hong Kong</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2015</study_first_submitted>
  <study_first_submitted_qc>February 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 9, 2015</study_first_posted>
  <results_first_submitted>January 25, 2017</results_first_submitted>
  <results_first_submitted_qc>March 14, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">April 25, 2017</results_first_posted>
  <last_update_submitted>March 14, 2017</last_update_submitted>
  <last_update_submitted_qc>March 14, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese University of Hong Kong</investigator_affiliation>
    <investigator_full_name>Andrea On Yan Luk</investigator_full_name>
    <investigator_title>Assocoiate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Hyperglycemia</mesh_term>
    <mesh_term>Prediabetic State</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted at the Diabetes and Endocrine Research Centre, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong SAR.</recruitment_details>
      <pre_assignment_details>77 subjects were screened and 60 subjects met the eligibility criteria to be randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BTI320 4 Grams</title>
          <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
        </group>
        <group group_id="P2">
          <title>BTI320 8 Grams</title>
          <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
        </group>
        <group group_id="P3">
          <title>BTI320 Matching Placebo</title>
          <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="24"/>
                <participants group_id="P2" count="24"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="23"/>
                <participants group_id="P3" count="12"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>BTI320 4 Grams</title>
          <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
        </group>
        <group group_id="B2">
          <title>BTI320 8 Grams</title>
          <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
        </group>
        <group group_id="B3">
          <title>BTI320 Matching Placebo</title>
          <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="24"/>
            <count group_id="B2" value="24"/>
            <count group_id="B3" value="12"/>
            <count group_id="B4" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.1" spread="8.6"/>
                    <measurement group_id="B2" value="58.5" spread="8.5"/>
                    <measurement group_id="B3" value="57.1" spread="10.9"/>
                    <measurement group_id="B4" value="56.4" spread="9.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="32"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="24"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="74.2" spread="16.9"/>
                    <measurement group_id="B2" value="71.0" spread="16.2"/>
                    <measurement group_id="B3" value="63.9" spread="20.0"/>
                    <measurement group_id="B4" value="70.9" spread="17.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body mass index</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28.0" spread="5.8"/>
                    <measurement group_id="B2" value="26.9" spread="4.4"/>
                    <measurement group_id="B3" value="25.1" spread="4.3"/>
                    <measurement group_id="B4" value="27.0" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist circumference</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95.0" spread="15.6"/>
                    <measurement group_id="B2" value="90.6" spread="9.1"/>
                    <measurement group_id="B3" value="88.0" spread="15.7"/>
                    <measurement group_id="B4" value="91.8" spread="13.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Systolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="121.7" spread="13.2"/>
                    <measurement group_id="B2" value="125.4" spread="16.2"/>
                    <measurement group_id="B3" value="127.8" spread="8.7"/>
                    <measurement group_id="B4" value="124.0" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diastolic blood pressure</title>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="78.4" spread="6.8"/>
                    <measurement group_id="B2" value="78.7" spread="7.2"/>
                    <measurement group_id="B3" value="80.4" spread="7.3"/>
                    <measurement group_id="B4" value="78.9" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fructosamine</title>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="268.5" spread="18.3"/>
                    <measurement group_id="B2" value="272.2" spread="20.2"/>
                    <measurement group_id="B3" value="278.9" spread="22.0"/>
                    <measurement group_id="B4" value="272.1" spread="19.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>HbA1c</title>
          <description>Glycated hemoglobin</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.0" spread="0.3"/>
                    <measurement group_id="B2" value="6.0" spread="0.3"/>
                    <measurement group_id="B3" value="6.1" spread="0.3"/>
                    <measurement group_id="B4" value="6.0" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Total cholesterol</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.9" spread="1.1"/>
                    <measurement group_id="B2" value="4.9" spread="1.0"/>
                    <measurement group_id="B3" value="5.3" spread="0.8"/>
                    <measurement group_id="B4" value="5.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Impaired fasting glucose</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Impaired glucose tolerance</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Impaired fasting glucose and impaired glucose tolerance</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Normal glucose tolerance</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>1-hour post-prandial glucose AUC</title>
          <description>1-hour post-prandial glucose incremental area under curve on continuous glucose monitoring system</description>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.91" spread="0.53"/>
                    <measurement group_id="B2" value="6.22" spread="0.72"/>
                    <measurement group_id="B3" value="6.33" spread="0.64"/>
                    <measurement group_id="B4" value="6.12" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>2-hour post-prandial glucose AUC</title>
          <description>2-hour post-prandial glucose incremental area under curve on continuous glucose monitoring system</description>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12.68" spread="1.21"/>
                    <measurement group_id="B2" value="13.64" spread="1.87"/>
                    <measurement group_id="B3" value="13.49" spread="1.43"/>
                    <measurement group_id="B4" value="13.22" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>3-hour post-prandial glucose AUC</title>
          <description>3-hour post-prandial glucose incremental area under curve on continuous glucose monitoring system</description>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18.90" spread="1.69"/>
                    <measurement group_id="B2" value="20.20" spread="2.59"/>
                    <measurement group_id="B3" value="20.20" spread="2.20"/>
                    <measurement group_id="B4" value="19.68" spread="2.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>72 hour AUC-180</title>
          <description>Area under curve for glucose levels &gt;180 mg/dL on continuous glucose monitoring system</description>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.40" spread="1.85"/>
                    <measurement group_id="B2" value="1.71" spread="3.35"/>
                    <measurement group_id="B3" value="2.73" spread="7.64"/>
                    <measurement group_id="B4" value="1.39" spread="4.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean blood glucose</title>
          <description>Mean blood glucose on continuous glucose monitoring system</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6.01" spread="0.45"/>
                    <measurement group_id="B2" value="6.20" spread="0.63"/>
                    <measurement group_id="B3" value="6.45" spread="0.54"/>
                    <measurement group_id="B4" value="6.18" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean post-meal maximum glucose</title>
          <description>Mean post-meal maximum glucose on continuous glucose monitoring system</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.45" spread="0.75"/>
                    <measurement group_id="B2" value="8.20" spread="1.31"/>
                    <measurement group_id="B3" value="8.07" spread="1.00"/>
                    <measurement group_id="B4" value="7.88" spread="1.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Mean amplitude of glucose excursion</title>
          <description>Mean amplitude of glucose excursion on continuous glucose monitoring system</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2.06" spread="0.69"/>
                    <measurement group_id="B2" value="2.68" spread="1.01"/>
                    <measurement group_id="B3" value="3.21" spread="3.16"/>
                    <measurement group_id="B4" value="2.55" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Percentage coefficient of variation</title>
          <description>Percentage coefficient of variation on continuous glucose monitoring system</description>
          <units>%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15.49" spread="4.43"/>
                    <measurement group_id="B2" value="19.07" spread="6.61"/>
                    <measurement group_id="B3" value="18.00" spread="7.60"/>
                    <measurement group_id="B4" value="17.46" spread="6.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Standard deviation</title>
          <description>Standard deviation on continuous glucose monitoring system</description>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0.93" spread="0.28"/>
                    <measurement group_id="B2" value="1.19" spread="0.44"/>
                    <measurement group_id="B3" value="1.18" spread="0.59"/>
                    <measurement group_id="B4" value="1.09" spread="0.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</title>
        <time_frame>From baseline to Week 4</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320.</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Serum Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320.</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="24"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="14.1"/>
                    <measurement group_id="O2" value="-9.4" spread="8.9"/>
                    <measurement group_id="O3" value="-8.8" spread="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>2.46</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.28</ci_lower_limit>
            <ci_upper_limit>11.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.72</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.57</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.3</ci_lower_limit>
            <ci_upper_limit>7.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System</title>
        <description>Changes in 3-hour post-prandial glucose incremental area under curve on continuous glucose monitoring system from baseline to Week 16.
Note that this is not a pharmacokinetic study and this is not pharmacokinetic data as we are not measuring drug levels. Here we are examining glucose levels after meals as one of the anticipated glycemic outcomes of using glucose-lowering therapy (BTI320 in this case). With data-analysis based on continuous glucose monitoring, it is conventional to present post-prandial (i.e. post-meal) glucose incremental area under curve at up to 3 hours. It is not meaningful to look at post-meal glucose changes at more than 3 hours after meal for the obvious reason that subject might have taken another meal by then.</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System</title>
          <description>Changes in 3-hour post-prandial glucose incremental area under curve on continuous glucose monitoring system from baseline to Week 16.
Note that this is not a pharmacokinetic study and this is not pharmacokinetic data as we are not measuring drug levels. Here we are examining glucose levels after meals as one of the anticipated glycemic outcomes of using glucose-lowering therapy (BTI320 in this case). With data-analysis based on continuous glucose monitoring, it is conventional to present post-prandial (i.e. post-meal) glucose incremental area under curve at up to 3 hours. It is not meaningful to look at post-meal glucose changes at more than 3 hours after meal for the obvious reason that subject might have taken another meal by then.</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.07" spread="1.99"/>
                    <measurement group_id="O2" value="-0.65" spread="1.93"/>
                    <measurement group_id="O3" value="-0.68" spread="1.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.25</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.91</ci_lower_limit>
            <ci_upper_limit>1.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.03</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose BTI320 and High Dose BTI320 Compared With Placebo in Mean Post-meal Maximum Glucose on Continuous Glucose Monitoring System</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose BTI320 and High Dose BTI320 Compared With Placebo in Mean Post-meal Maximum Glucose on Continuous Glucose Monitoring System</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.13" spread="0.99"/>
                    <measurement group_id="O2" value="-0.36" spread="0.87"/>
                    <measurement group_id="O3" value="-0.14" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.50</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.59</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.66</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Amplitude of Glucose Excursion on Continuous Glucose Monitoring System</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Amplitude of Glucose Excursion on Continuous Glucose Monitoring System</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.04" spread="0.77"/>
                    <measurement group_id="O2" value="-0.48" spread="0.88"/>
                    <measurement group_id="O3" value="-0.92" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.62</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.44</ci_lower_limit>
            <ci_upper_limit>0.73</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.97</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>0.55</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Blood Glucose on Continuous Glucose Monitoring System</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Blood Glucose on Continuous Glucose Monitoring System</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.52"/>
                    <measurement group_id="O2" value="-0.06" spread="0.50"/>
                    <measurement group_id="O3" value="-0.32" spread="0.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.49</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve for Glucose Levels &gt;180mg/dL on Continuous Glucose Monitoring System</title>
        <description>Area under curve for glucose levels &gt;180 mg/dL over 72 hours</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve for Glucose Levels &gt;180mg/dL on Continuous Glucose Monitoring System</title>
          <description>Area under curve for glucose levels &gt;180 mg/dL over 72 hours</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.19" spread="2.58"/>
                    <measurement group_id="O2" value="-1.67" spread="3.51"/>
                    <measurement group_id="O3" value="-1.38" spread="9.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.84</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.88</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.34</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.18</ci_lower_limit>
            <ci_upper_limit>0.51</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Glucose on Continuous Glucose Monitoring System</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Glucose on Continuous Glucose Monitoring System</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.09" spread="0.32"/>
                    <measurement group_id="O2" value="-0.23" spread="0.31"/>
                    <measurement group_id="O3" value="-0.14" spread="0.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation on Continuous Glucose Monitoring System</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation on Continuous Glucose Monitoring System</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>% of coefficient of variation</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.6" spread="4.4"/>
                    <measurement group_id="O2" value="-3.5" spread="4.5"/>
                    <measurement group_id="O3" value="-1.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.43</ci_lower_limit>
            <ci_upper_limit>2.05</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.75</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.72</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in HbA1c in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in HbA1c in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>percent glycated hemoglobin</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.19"/>
                    <measurement group_id="O2" value="-0.02" spread="0.16"/>
                    <measurement group_id="O3" value="-0.04" spread="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Fructosamine in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="18.6"/>
                    <measurement group_id="O2" value="-6.8" spread="12.0"/>
                    <measurement group_id="O3" value="-9.8" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.83</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.17</ci_lower_limit>
            <ci_upper_limit>11.45</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-11.1</ci_lower_limit>
            <ci_upper_limit>9.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of Glucose During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
        <description>Changes in area under curve of glucose from 0 minute to 120 minutes from baseline to Week 16</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of Glucose During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
          <description>Changes in area under curve of glucose from 0 minute to 120 minutes from baseline to Week 16</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-63.6" spread="103.9"/>
                    <measurement group_id="O2" value="-24.5" spread="132.2"/>
                    <measurement group_id="O3" value="-84.9" spread="150.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.75</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-13.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-99.6</ci_lower_limit>
            <ci_upper_limit>72.3</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>40.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-43.9</ci_lower_limit>
            <ci_upper_limit>123.9</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of Insulin During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
        <description>Changes in area under curve of insulin from 0 minute to 120 minutes from baseline to Week 16</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of Insulin During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
          <description>Changes in area under curve of insulin from 0 minute to 120 minutes from baseline to Week 16</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mIU/L*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1533.7" spread="3171.6"/>
                    <measurement group_id="O2" value="-382.8" spread="2781.6"/>
                    <measurement group_id="O3" value="-1225.8" spread="3922.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.23</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-980.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2604</ci_lower_limit>
            <ci_upper_limit>643.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>323.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1269</ci_lower_limit>
            <ci_upper_limit>1916.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of C-peptide During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
        <description>Changes in area under curve of C-peptide from 0 minute to 120 minutes from baseline to Week 16</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Area Under Curve of C-peptide During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
          <description>Changes in area under curve of C-peptide from 0 minute to 120 minutes from baseline to Week 16</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>ug/L*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-56.2" spread="193.1"/>
                    <measurement group_id="O2" value="-22.9" spread="170.9"/>
                    <measurement group_id="O3" value="-120.8" spread="257.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>15.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-99.6</ci_lower_limit>
            <ci_upper_limit>129.6</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>60.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-52.5</ci_lower_limit>
            <ci_upper_limit>172.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Glucagon-like Peptide 1 During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
        <description>Changes in area under curve of glucagon-like peptide-1 from 0 minute to 120 minutes from baseline to Week 16</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Glucagon-like Peptide 1 During Standard Meal Tolerance Test From 0 Minute to 120 Minutes</title>
          <description>Changes in area under curve of glucagon-like peptide-1 from 0 minute to 120 minutes from baseline to Week 16</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>pmol/L*minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117.0" spread="340.6"/>
                    <measurement group_id="O2" value="130.9" spread="514.1"/>
                    <measurement group_id="O3" value="107.9" spread="197.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-120.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-385.3</ci_lower_limit>
            <ci_upper_limit>144.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>49.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-198.1</ci_lower_limit>
            <ci_upper_limit>296.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Subjects With Impaired Fasting Glucose or Impaired Glucose Tolerance in Low Dose BTI320, High Dose BTI320 and Placebo Group</title>
        <description>Proportion of subjects with impaired fasting glucose, impaired glucose tolerance, both impaired fasting glucose and impaired glucose tolerance, HbA1c 5.7-6.4%, or type 2 diabetes at 30 days post-treatment</description>
        <time_frame>From baseline to 30 days post-treatment</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Subjects With Impaired Fasting Glucose or Impaired Glucose Tolerance in Low Dose BTI320, High Dose BTI320 and Placebo Group</title>
          <description>Proportion of subjects with impaired fasting glucose, impaired glucose tolerance, both impaired fasting glucose and impaired glucose tolerance, HbA1c 5.7-6.4%, or type 2 diabetes at 30 days post-treatment</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100"/>
                    <measurement group_id="O2" value="95.7"/>
                    <measurement group_id="O3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Blood Pressures in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <description>Changes in systolic blood pressures from baseline to Week 16</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Blood Pressures in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <description>Changes in systolic blood pressures from baseline to Week 16</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" spread="10.6"/>
                    <measurement group_id="O2" value="-0.7" spread="13.5"/>
                    <measurement group_id="O3" value="-3.5" spread="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-9.8</ci_lower_limit>
            <ci_upper_limit>5.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.79</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.0</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-6.6</ci_lower_limit>
            <ci_upper_limit>8.6</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Waist Circumference in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Waist Circumference in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.5" spread="3.4"/>
                    <measurement group_id="O2" value="-1.5" spread="3.4"/>
                    <measurement group_id="O3" value="-1.8" spread="3.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.4</ci_lower_limit>
            <ci_upper_limit>1.8</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.0</ci_lower_limit>
            <ci_upper_limit>3.1</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Body Weight in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Body Weight in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.7" spread="2.4"/>
                    <measurement group_id="O2" value="-0.5" spread="1.9"/>
                    <measurement group_id="O3" value="-0.1" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-1.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.2</ci_lower_limit>
            <ci_upper_limit>-0.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.86</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.7</ci_lower_limit>
            <ci_upper_limit>1.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Lipids in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <description>Changes in total cholesterol from baseline to Week 16.</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Lipids in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <description>Changes in total cholesterol from baseline to Week 16.</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0" spread="0.75"/>
                    <measurement group_id="O2" value="-0.2" spread="0.56"/>
                    <measurement group_id="O3" value="-0.15" spread="0.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.90</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.39</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.63</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in High-sensitivity C-reactive Protein in Subjects Treated With High Dose and Low Dose BTI320 Compared Placebo</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in High-sensitivity C-reactive Protein in Subjects Treated With High Dose and Low Dose BTI320 Compared Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.85" spread="5.78"/>
                    <measurement group_id="O2" value="0.09" spread="2.00"/>
                    <measurement group_id="O3" value="-0.89" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.32</ci_lower_limit>
            <ci_upper_limit>2.57</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.24</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>3.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Urate in Subjects Treated With High Dose and Lose Dose BTI320 Compared to Placebo</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Urate in Subjects Treated With High Dose and Lose Dose BTI320 Compared to Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.008" spread="0.054"/>
                    <measurement group_id="O2" value="0.006" spread="0.053"/>
                    <measurement group_id="O3" value="-0.015" spread="0.036"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.93</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.002</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.035</ci_lower_limit>
            <ci_upper_limit>0.038</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.40</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.015</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.021</ci_lower_limit>
            <ci_upper_limit>0.051</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Quality of Life Measures in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <description>Changes in WHOQOL-BREF physical health domain score from baseline to Week 16. This is a sub-scale of the WHOQOL-BREF. Possible scores range from minimal of 4 to maximum of 20. Higher score indicate better physical health domain.</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Quality of Life Measures in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <description>Changes in WHOQOL-BREF physical health domain score from baseline to Week 16. This is a sub-scale of the WHOQOL-BREF. Possible scores range from minimal of 4 to maximum of 20. Higher score indicate better physical health domain.</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" spread="1.4"/>
                    <measurement group_id="O2" value="0.0" spread="1.3"/>
                    <measurement group_id="O3" value="0.1" spread="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.2</ci_lower_limit>
            <ci_upper_limit>0.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.36</p_value>
            <p_value_desc>The p-value of treatment effects relative to placebo was obtained by ANCOVA analysis comparing the outcome values adjusted for age, gender and baseline measurements.</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.4</ci_lower_limit>
            <ci_upper_limit>1.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Measures of Food Satiety in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <description>Changes to question of &quot;how full do you feel&quot; in the Appetite Questionnaire adopted from Hill and Blundell from baseline and Week 16. Scale score ranges from minimum of 0 to maximum of 10. 10 being the most full and 0 being the least full.</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Measures of Food Satiety in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <description>Changes to question of &quot;how full do you feel&quot; in the Appetite Questionnaire adopted from Hill and Blundell from baseline and Week 16. Scale score ranges from minimum of 0 to maximum of 10. 10 being the most full and 0 being the least full.</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.4" spread="2.7"/>
                    <measurement group_id="O2" value="1.0" spread="3.2"/>
                    <measurement group_id="O3" value="1.3" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.09</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.82</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Measures of Nutritional Intake in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <description>Changes in daily calories intake from baseline to Week 16</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Measures of Nutritional Intake in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <description>Changes in daily calories intake from baseline to Week 16</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>kcal</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-237.4" spread="358.8"/>
                    <measurement group_id="O2" value="-75.0" spread="486.2"/>
                    <measurement group_id="O3" value="-320.9" spread="794.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.68</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.26</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Measures of Exercise in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <description>Changes in the number of days per week that the subject spent walking for at least 10 minutes from baseline to Week 16</description>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Measures of Exercise in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <description>Changes in the number of days per week that the subject spent walking for at least 10 minutes from baseline to Week 16</description>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.1" spread="1.7"/>
                    <measurement group_id="O2" value="-0.5" spread="2.1"/>
                    <measurement group_id="O3" value="0.2" spread="0.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.30</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 1 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 1 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.11" lower_limit="-0.18" upper_limit="0.41"/>
                    <measurement group_id="O2" value="-0.07" lower_limit="-0.33" upper_limit="0.19"/>
                    <measurement group_id="O3" value="-0.15" lower_limit="-0.49" upper_limit="0.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.30</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.13</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.32</ci_lower_limit>
            <ci_upper_limit>0.04</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 2 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 2 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.08" lower_limit="-0.62" upper_limit="0.78"/>
                    <measurement group_id="O2" value="-0.51" lower_limit="-1.10" upper_limit="0.08"/>
                    <measurement group_id="O3" value="-0.31" lower_limit="-0.92" upper_limit="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.59</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.01</ci_lower_limit>
            <ci_upper_limit>-0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.42</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.57</ci_lower_limit>
            <ci_upper_limit>0.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 3 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean 3 Hour Post-prandial Glucose Incremental Area Under Curve on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L*hour</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14" lower_limit="-0.85" upper_limit="1.14"/>
                    <measurement group_id="O2" value="-0.68" lower_limit="-1.51" upper_limit="0.14"/>
                    <measurement group_id="O3" value="-0.69" lower_limit="-1.59" upper_limit="0.21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.02</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.74</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.35</ci_lower_limit>
            <ci_upper_limit>-0.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.57</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 1 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 1 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="-0.20" upper_limit="0.44"/>
                    <measurement group_id="O2" value="-0.08" lower_limit="-0.36" upper_limit="0.20"/>
                    <measurement group_id="O3" value="-0.16" lower_limit="-0.53" upper_limit="0.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.32</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.14</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.05</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 2 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 2 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.12" lower_limit="-0.24" upper_limit="0.48"/>
                    <measurement group_id="O2" value="-0.19" lower_limit="-0.49" upper_limit="0.11"/>
                    <measurement group_id="O3" value="-0.08" lower_limit="-0.42" upper_limit="0.26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.31</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>-0.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.38</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.12</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 3 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in 3 Hour Post-prandial Mean Blood Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-0.19" upper_limit="0.48"/>
                    <measurement group_id="O2" value="-0.14" lower_limit="-0.40" upper_limit="0.12"/>
                    <measurement group_id="O3" value="-0.04" lower_limit="-0.34" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>-0.07</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Blood Glucose During 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Blood Glucose During 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.27" upper_limit="0.17"/>
                    <measurement group_id="O2" value="-0.05" lower_limit="-0.26" upper_limit="0.16"/>
                    <measurement group_id="O3" value="-0.16" lower_limit="-0.38" upper_limit="0.06"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.40</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.10</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.38</ci_lower_limit>
            <ci_upper_limit>0.03</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Post-prandial Maximum Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Post-prandial Maximum Glucose on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.15" lower_limit="-0.34" upper_limit="0.64"/>
                    <measurement group_id="O2" value="-0.38" lower_limit="-0.75" upper_limit="0.00"/>
                    <measurement group_id="O3" value="-0.14" lower_limit="-0.51" upper_limit="0.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.01</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.67</ci_lower_limit>
            <ci_upper_limit>-0.12</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.54</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Post-prandial Maximum Glucose During 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Mean Post-prandial Maximum Glucose During 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.10" lower_limit="-0.38" upper_limit="0.58"/>
                    <measurement group_id="O2" value="-0.52" lower_limit="-0.91" upper_limit="-0.12"/>
                    <measurement group_id="O3" value="-0.35" lower_limit="-0.82" upper_limit="0.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.81</ci_lower_limit>
            <ci_upper_limit>-0.03</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.63</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.48</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 1 Hour Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 1 Hour Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="-0.15" upper_limit="0.15"/>
                    <measurement group_id="O2" value="-0.18" lower_limit="-0.31" upper_limit="-0.05"/>
                    <measurement group_id="O3" value="-0.05" lower_limit="-0.19" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.05</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.73</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 2 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 2 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.02" lower_limit="-0.12" upper_limit="0.16"/>
                    <measurement group_id="O2" value="-0.13" lower_limit="-0.25" upper_limit="0.00"/>
                    <measurement group_id="O3" value="-0.01" lower_limit="-0.13" upper_limit="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 3 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose During 3 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.01" lower_limit="-0.13" upper_limit="0.15"/>
                    <measurement group_id="O2" value="-0.12" lower_limit="-0.23" upper_limit="-0.01"/>
                    <measurement group_id="O3" value="-0.02" lower_limit="-0.14" upper_limit="0.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.15</ci_lower_limit>
            <ci_upper_limit>0.00</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.46</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.10</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Standard Deviation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.05" lower_limit="-0.20" upper_limit="0.10"/>
                    <measurement group_id="O2" value="-0.20" lower_limit="-0.33" upper_limit="-0.07"/>
                    <measurement group_id="O3" value="-0.18" lower_limit="-0.61" upper_limit="0.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.03</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>-0.02</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.87</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.15</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 1 Hour Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 1 Hour Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>% of coefficient of variation</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.26" lower_limit="-1.99" upper_limit="1.47"/>
                    <measurement group_id="O2" value="-2.46" lower_limit="-4.03" upper_limit="-0.90"/>
                    <measurement group_id="O3" value="-0.60" lower_limit="-2.18" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.34</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.46</ci_lower_limit>
            <ci_upper_limit>0.50</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.64</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 2 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 2 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>% of coefficient of variation</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.06" lower_limit="-1.54" upper_limit="1.42"/>
                    <measurement group_id="O2" value="-1.28" lower_limit="-2.71" upper_limit="0.16"/>
                    <measurement group_id="O3" value="-0.01" lower_limit="-1.67" upper_limit="1.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.17</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.62</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.50</ci_lower_limit>
            <ci_upper_limit>0.26</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.46</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 3 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 3 Hours Post-prandial on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>% of coefficient of variation</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.18" lower_limit="-1.73" upper_limit="1.38"/>
                    <measurement group_id="O2" value="-1.37" lower_limit="-2.67" upper_limit="-0.08"/>
                    <measurement group_id="O3" value="-0.33" lower_limit="-1.93" upper_limit="1.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.18</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-0.65</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.62</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.37</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.51</ci_lower_limit>
            <ci_upper_limit>1.36</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Subjects Treated With Low Dose and High Dose BTI320 Compared With Placebo in Percent Coefficient of Variation of Blood Glucose Over 24 Hours on Continuous Glucose Monitoring System Repeated Measures Analysis</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>% of coefficient of variation</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" lower_limit="-2.99" upper_limit="1.31"/>
                    <measurement group_id="O2" value="-3.04" lower_limit="-4.95" upper_limit="-1.13"/>
                    <measurement group_id="O3" value="-2.68" lower_limit="-10.09" upper_limit="4.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.06</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>-2.14</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.36</ci_lower_limit>
            <ci_upper_limit>0.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.69</p_value>
            <p_value_desc>The p-value of treatment effects (reference to placebo) were obtained by mixed effect model analysis comparing the outcome values adjusted with repeated measures, ages and gender.</p_value_desc>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Net)</param_type>
            <param_value>0.43</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-1.71</ci_lower_limit>
            <ci_upper_limit>2.58</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Serum Creatinine in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <time_frame>From baseline to Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Serum Creatinine in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>umol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="7.0"/>
                    <measurement group_id="O2" value="-3.5" spread="8.5"/>
                    <measurement group_id="O3" value="-7.0" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.29</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Measures of Liver Function in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <time_frame>From baseline to Week 4, Week 8, Week 12, and Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320.</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Measures of Liver Function in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320.</population>
          <units>IU/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="12.5"/>
                    <measurement group_id="O2" value="1.4" spread="8.5"/>
                    <measurement group_id="O3" value="-0.9" spread="10.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.41</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.48</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Complete Blood Count in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
        <time_frame>From baseline to Week 4, Week 8, Week 12, and Week 16</time_frame>
        <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
        <group_list>
          <group group_id="O1">
            <title>BTI320 4 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O2">
            <title>BTI320 8 Grams</title>
            <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
          </group>
          <group group_id="O3">
            <title>BTI320 Matching Placebo</title>
            <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Complete Blood Count in Subjects Treated With High Dose and Low Dose BTI320 Compared to Placebo</title>
          <population>Intention to treat, as defined by all subjects who have received at least one dose of BTI320</population>
          <units>g/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="12"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3" spread="0.4"/>
                    <measurement group_id="O2" value="-0.4" spread="0.5"/>
                    <measurement group_id="O3" value="-0.4" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.61</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.89</p_value>
            <p_value_desc>The univariate p-value of treatment group was obtained by t-tests comparing the changes to that of placebo group</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>16 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BTI320 4 Grams</title>
          <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
        </group>
        <group group_id="E2">
          <title>BTI320 8 Grams</title>
          <description>three times daily, oral for 16 weeks
BTI320: BTI320, also known as SUGARDOWN®, is derived from galactomanan which blocks key enzymes that break down carbohydrate in the gut. BTI320 therefore helps to slow down the absorption of carbohydrates to lower post-meal blood sugar.</description>
        </group>
        <group group_id="E3">
          <title>BTI320 Matching Placebo</title>
          <description>2 tablets three times daily, oral for 16 weeks
BTI320 matching placebo: Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>High grade osteosarcoma at left distal femur</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="24"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="24"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="24"/>
                <counts group_id="E2" events="6" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="24"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="24"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Frequent bowel movements</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="24"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="24"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="24"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="12"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr Andrea Luk</name_or_title>
      <organization>The Chinese University of Hong Kong</organization>
      <phone>852-26324276</phone>
      <email>andrealuk@cuhk.edu.hk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

